---
title: "Avalo Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295095149.md"
datetime: "2026-08-06T11:03:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295095149.md)
  - [en](https://longbridge.com/en/news/295095149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295095149.md)
generator: "portal-rs"
---

# Avalo Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.83.

EBIT: As of FY2026 Q2, the actual value is USD -33.58 M.

#### Cash, Cash Equivalents and Investments

Avalo Therapeutics, Inc. reported cash, cash equivalents, and investments totaling $472.2 million as of June 30, 2026, which is expected to provide a financial runway into 2029.

#### Net Cash Used in Operating Activities

For the six months ended June 30, 2026, net cash used in operating activities was - $37.7 million.

#### Balance Sheet Highlights (In thousands)

As of June 30, 2026, Avalo Therapeutics, Inc. had cash and cash equivalents of $85,382 thousand, short-term investments of $314,894 thousand, and long-term investments of $71,878 thousand, contributing to total assets of $490,783 thousand. Total liabilities were $42,123 thousand, and total stockholders’ equity was $448,660 thousand. This compares to total assets of $116,458 thousand, total liabilities of $33,409 thousand, and total stockholders’ equity of $83,049 thousand as of December 31, 2025.

#### Statements of Operations Highlights (In thousands)

**Three Months Ended June 30, 2026 vs. June 30, 2025:**Research and development expenses increased by $9.3 million to $23,418 thousand in 2026 from $14,074 thousand in 2025, primarily due to a $10.0 million development milestone for abdakibart. General and administrative expenses rose by $2.9 million to $8,099 thousand in 2026 from $5,242 thousand in 2025, mainly due to stock-based compensation expense. Total operating expenses were $31,517 thousand in 2026 compared to $19,316 thousand in 2025. The loss from operations was - $31,517 thousand in 2026, an increase from - $19,316 thousand in 2025. Net loss increased by $15.6 million to - $36,358 thousand in 2026 from - $20,765 thousand in 2025, largely driven by a $12.2 million increase in operating expenses. Comprehensive loss was - $36,935 thousand in 2026 versus - $20,799 thousand in 2025.

**Six Months Ended June 30, 2026 vs. June 30, 2025:**Research and development expenses were $37,466 thousand in 2026, up from $23,195 thousand in 2025. General and administrative expenses increased to $14,953 thousand in 2026 from $10,789 thousand in 2025. Total operating expenses reached $52,419 thousand in 2026, compared to $33,984 thousand in 2025. The loss from operations was - $52,419 thousand in 2026, an increase from - $33,984 thousand in 2025. Net loss was - $55,988 thousand in 2026, compared to - $33,914 thousand in 2025. Comprehensive loss was - $56,639 thousand in 2026 versus - $33,948 thousand in 2025.

#### Operational Highlights

Avalo Therapeutics, Inc. plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027. The company also expanded its pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, for which an Investigational New Drug (IND) submission is planned for the first half of 2027. Ron Philip was appointed to the Board of Directors, and Avalo Therapeutics, Inc. was added to the Russell 2000® and Russell 3000® Indexes.

#### Outlook / Guidance

Avalo Therapeutics, Inc. anticipates its current cash, cash equivalents, and investments of $472.2 million will fund operations into 2029. The company expects to initiate a registrational Phase 3 program for abdakibart in HS and submit an IND application for AVTX-010 in the first half of 2027.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)

## Related News & Research

- [Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 million](https://longbridge.com/en/news/296395368.md)
- [Panatlantica board signs off on Q2 2026 financial statements in quarterly ITR filing](https://longbridge.com/en/news/296821226.md)
- [Equifax declares Q3 2026 distribution of R$ 2.02 per unit, payable Sept. 22](https://longbridge.com/en/news/296941296.md)
- [FluoGuide A/S Publishes Interim Report for Q2 2026](https://longbridge.com/en/news/296864861.md)
- [Aliperti board clears Q2 2026 financial statements despite dissenting vote](https://longbridge.com/en/news/296634714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**